Cargando…
Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.”
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243255/ https://www.ncbi.nlm.nih.gov/pubmed/18219567 http://dx.doi.org/10.1007/s10557-008-6079-x |
| _version_ | 1782150638149304320 |
|---|---|
| author | Belonje, A. M. S. de Boer, R. A. Voors, A. A. |
| author_facet | Belonje, A. M. S. de Boer, R. A. Voors, A. A. |
| author_sort | Belonje, A. M. S. |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2243255 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-22432552008-02-14 Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” Belonje, A. M. S. de Boer, R. A. Voors, A. A. Cardiovasc Drugs Ther Article Springer US 2008-01-25 2008-02 /pmc/articles/PMC2243255/ /pubmed/18219567 http://dx.doi.org/10.1007/s10557-008-6079-x Text en © The Author(s) 2008 |
| spellingShingle | Article Belonje, A. M. S. de Boer, R. A. Voors, A. A. Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title | Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title_full | Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title_fullStr | Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title_full_unstemmed | Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title_short | Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.” |
| title_sort | recombinant human epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both?: editorial to: “correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by pappas et al.” |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243255/ https://www.ncbi.nlm.nih.gov/pubmed/18219567 http://dx.doi.org/10.1007/s10557-008-6079-x |
| work_keys_str_mv | AT belonjeams recombinanthumanepotreatmentbeneficialinchronickidneydiseasechronicheartfailureorbotheditorialtocorrectionofanemiawitherythropoietininchronickidneydiseasestage3or4effectsoncardiacperformancebypappasetal AT deboerra recombinanthumanepotreatmentbeneficialinchronickidneydiseasechronicheartfailureorbotheditorialtocorrectionofanemiawitherythropoietininchronickidneydiseasestage3or4effectsoncardiacperformancebypappasetal AT voorsaa recombinanthumanepotreatmentbeneficialinchronickidneydiseasechronicheartfailureorbotheditorialtocorrectionofanemiawitherythropoietininchronickidneydiseasestage3or4effectsoncardiacperformancebypappasetal |